



Syntaxin to Present at Biotech Showcase™ 2012

Oxford (UK), 3 January 2012 – Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies targeting cell secretion pathways, announced today that Dr Melanie Lee, Chief Executive Officer of Syntaxin, will present at the Biotech Showcase™ 2012 Conference on Tuesday, 10 January 2012 at 10:30PST/18:30GMT, in San Francisco, USA. Syntaxin will also participate in the pre-scheduled partnering meetings at the conference.

-Ends-

For further information please contact:

Syntaxin

Melanie Lee, CEO
Nigel Clark, CBO
Tel: +44 (0)1235 552161

Media

M:Communications

Mary-Jane Elliott, Emma Thompson, Claire Dickinson
Tel: +44 (0)20 7920 2330
Email: Syntaxin@mcomgroup.com

About Syntaxin

Syntaxin discovers and develops a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSIs) that treat disease through selective inhibition of cell secretory pathways. It is developing TSIs for the treatment of a range of diseases, including endocrine, sensory and respiratory conditions and oncology. In addition, Syntaxin is applying its expertise in botulinum toxin biology to identifying new therapeutic opportunities.

Syntaxin's Board, chaired by Dr Russell Greig, collaborates with the Executive Management Team, led by CEO Dr Melanie Lee, to provide a wealth of pharmaceutical industry experience to Syntaxin. Syntaxin was founded in late 2005 through a spinout of intellectual property and scientists from the Health Protection Agency, and has an internationally recognised depth of experience in botulinum neurotoxin biology.

Syntaxin's Targeted Secretion Inhibitors (TSI) technology platform

Syntaxin's TSI products are biological molecules, synthesized in microbial cell culture, that selectively bind to their chosen targeted cells and become internalised to deliver endopeptidases into the cell's cytoplasm, thereby preventing further vesicular secretion. A single dose can provide an extended duration of action from weeks to months.

The company owns dominant patents and know-how in the design, manufacture and use of novel cellular TSIs that are based on engineered botulinum toxins. It has established a strong IP base with over 50 granted patents covering the platform and products. Syntaxin is



backed by a strong investor base including: Abingworth, SR One, LSP, JJDC, Lundbeckfond Ventures, Ipsen, Seventure and Quest.

For further information visit the company's website www.syntaxin.com

About Biotech Showcase (Innovation – Opportunity – Collaboration)

Now in its fourth year, Biotech Showcase will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®. Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry. Visit our website for more information: www.ebdgroup.com/bts.